Ph.D., CSO and Co-Founder, TopoMD
Leads interdisciplinary collaborations developing approaches for integration and analysis of large-scale multi-‘omics data for the stratification of patient populations and characterisation at the level of the individual. James directs topological analysis for stratified and personalised medicine in the Unbiased BIOmarkers in PREDiction of respiratory disease outcomes (U-BIOPRED) programme and the Study of mechanisms of action of omalizumab in severe asthma (SoMOSA). Dr James Schofield co-founded, with Dr Fabio Strazzeri, Dr Paul Skipp and Dr Ruben Sanchez-Garcia, TopoMD which applies topological measurement of differential pathway modulation to define a patient’s pathological state. TopoMD shapes enable precision medicine, disease stratification, insights into disease mechanisms, drug target identification and cohort selection for drug development.
Clinical Dx Showcase: TopoMD
TopoMD measures the shape of biological pathway modulation, from standard global gene expression data, diagnostic of disease state.
Shapes Of Pathway Modulation For Molecular Diagnosis
TopoMD profiles the shape of biological pathway modulation from standard global gene expression data, enabling accurate molecular diagnosis for precision medicine, disease stratification, insights into disease mechanisms, drug target identification and cohort selection for drug development.